CVS Health's Omnicare unit has agreed to a $440 million settlement with the Department of Justice to resolve a nearly $950 million fraud judgment. The deal follows a 2025 jury verdict finding Omnicare submitted over 3.3 million fraudulent prescription claims between 2010 and 2018. The settlement is tied to Omnicare's pending sale to GenieRx Holdings, expected to close by year-end.
CVS Health's long-troubled Omnicare unit has reached a $440 million settlement with the Department of Justice, resolving a fraud judgment that had ballooned to nearly $950 million. The agreement calls for an initial $130 million payment within 14 days of the deal taking effect, with the remaining $310 million due by March 2028. CVS emphasized the settlement is not an admission of wrongdoing, calling it a pragmatic move to avoid "protracted and expensive litigation."
The case traces back to a 2015 whistleblower lawsuit filed by a former Omnicare pharmacist. A federal jury ruled in April 2025 that Omnicare submitted 3.3 million fraudulent prescription claims between 2010 and 2018, netting $135.6 million in improper overpayments. CVS itself was found to have pushed Omnicare to submit roughly 1 million of those claims, though the jury found no resulting injury to the federal government.
The settlement is contingent on the court-approved sale of Omnicare to GenieRx Holdings — a virtual care company backed by private equity — which is expected to close by the end of 2026.
By the Numbers:
Why it matters: This settlement closes a years-long legal saga involving one of the country's largest pharmacy services providers for long-term care facilities, signaling how fraud in prescription billing can carry massive financial and operational consequences — even for healthcare giants like CVS.
